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by bacteria of the oral biofilm. Several studies have shown that periodontitis is associated with increased levels
of serum inflammatory markers involved in atherosclerosis. Recently, there is an increasing number of trials
investigating the effect of scaling and root planing on reducing level of systemic inflammation between
periodontal maintenance visits in patients with coronary heart disease to decrease the inflammatory burden in
this targeted population and the risk of secondary cardiovascular event. Objective: The aim of this study is to
conduct a systematic review to investigate the effect of dental scaling and root planning on reducing the serum
levels of inflammatory markers in patients with stable coronary heart disease. Method: Electronic searches
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assessing the change in the level of serum inflammatory markers. Conclusion: There is a low evidence from
the current literature supporting the effect of scaling and root planing in reducing systemic inflammatory
markers including C-reactive protein, tumor necrosis factor-alpha, interleukin-6, and fibrinogen in patients
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Background: Coronary heart disease is a common manifestation of 
atherosclerosis. Various inflammatory markers including C-reactive protein (CRP), 
tumor necrosis factor- (TNF-), interleukin-6 (IL-6), and fibrinogen play role in the 
development of atherosclerosis. Periodontitis is the inflammation of teeth 
supporting structures initiated by bacteria of the oral biofilm. Several studies have 
shown that periodontitis is associated with increased levels of serum inflammatory 
markers involved in atherosclerosis. Recently, there is an increasing number of 
trials investigating the effect of scaling and root planing on reducing level of 
systemic inflammation between periodontal maintenance visits in patients with 
coronary heart disease to decrease the inflammatory burden in this targeted 
population and the risk of secondary cardiovascular event. Objective: The aim of 
this study is to conduct a systematic review to investigate the effect of dental 
scaling and root planning on reducing the serum levels of inflammatory markers in 
patients with stable coronary heart disease. Method: Electronic searches were 
conducted in PubMed, Scopus, Cochrane Library, ClinicalTrials.gov, World Health 
Organization (WHO) International Trials Registry Platform, and Google Scholar 
beta to identify randomized controlled trial evaluated the effect of scaling and root 
planing on the level of serum inflammatory markers in patients with stable coronary 
heart disease to those who have coronary heart disease but received no treatment 
or simple oral hygiene measures only. Results: A total of 358 studies were initially 
identified from the search; 4 studies met the inclusion criteria and were selected 
for this systematic review. All of the included studies have considered C-reactive 
protein (CRP) as a main outcome measure. Only one study considered evaluating 
the effect on fibrinogen, another study on interleukin-6 (IL-6), and two studies on 
tumor necrosis factor- (TNF-). In general, the results of the included randomized 
controlled trials appear to support the effectiveness of scaling and root planing in 
reducing serum levels of inflammatory markers. However, most of the studies 
involved small sample sizes except for one study, and there was inconsistency 
between the studies in the time considered for assessing the change in the level 
of serum inflammatory markers. Conclusion: There is a low evidence from the 
current literature supporting the effect of scaling and root planing in reducing 
systemic inflammatory markers including C-reactive protein (CRP), tumor necrosis 
factor- (TNF-), interleukin-6 (IL-6), and fibrinogen in patients with stable 
coronary heart disease. Future research should include observational studies to 
assess the effect of scaling and root planing in reducing the inflammatory burden 
in this targeted population and the risk of secondary cardiovascular event. 
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Effect of Dental Scaling and Root Planing on Serum 
Inflammatory Markers in Patients with Coronary Heart 
Disease: A Systematic Review 
 
 
 
Background: 
 
Coronary artery disease is the most common type of cardiovascular disease 
affecting 16.5 million Americans (Benjamin et al, 2017). Coronary heart disease is 
a common manifestation of atherosclerosis. Inflammation plays a pivotal role in the 
development of atherosclerosis and the acute activation of the vascular wall with 
consequent local thrombosis and vasoconstriction (Liuzzo, 2001). Various 
inflammatory markers express different aspects of the inflammatory processes that 
contribute to atherosclerosis (Ikonomidis et al, 2012). A decently studied serum 
inflammatory marker is the C-reactive protein. C-reactive protein is a non-specific 
highly sensitive systemic marker of inflammation and a predictor of incident 
coronary heart disease (Koenig et al, 1999). A cut-off level of high sensitivity C-
reactive protein (hs-CRP) of 2 mg/L seems to discriminate high from low risk 
patients with stable or unstable coronary disease or even apparently healthy 
individuals for short and long-term prognosis of cardiovascular event (Zakynthinos 
et al, 2009). Plasma fibrinogen have also been associated with atherosclerosis 
progression in patients with stable coronary heart disease (Danesh et al, 1998; 
Green et al, 2009; Shojaie et al, 2009). Moreover, Interleukin-6 plasma level could 
reflect the extent of inflammatory reactions in atherosclerotic vessels and improve 
the prediction of coronary heart disease risk (Luc et al, 2003). Recent large trial 
demonstrated that Interleukin-6 was independently associated with the risk of 
major coronary events in patients with stable coronary heart disease and may be 
a potential future target for the treatment of stable coronary heart disease (Held et 
al, 2017). During the past years, many efforts have been made to identify different 
risk factors for coronary heart disease and their contribution to systemic 
inflammation in order to offer targets for therapeutic and preventive interventions.  
 
    Mattila et al. (1989) conducted the first two case-control studies to examine the 
role of chronic dental infections including periodontitis as risk factors for coronary 
heart disease. Periodontitis is a chronic inflammation of teeth supporting 
structures. It involves a complex immune/inflammatory cascade that is initiated 
by the bacteria of the oral biofilm that forms naturally on the teeth (Cekici et al, 
2000).  The association between coronary heart disease and periodontitis has 
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been investigated by a significant body of evidence. A meta-analysis indicates 
that both the prevalence and incidence of coronary heart disease are significantly 
increased in periodontitis (Bahekar et al, 2007). Another systematic review and 
meta-analysis identifies periodontal disease as a risk factor for coronary heart 
disease that is independent of traditional coronary heart disease risk factors 
(Humphrey at al, 2008). Recent systematic review indicates the association 
between periodontitis and atherosclerosis, with elevated levels of inflammatory 
markers, mainly C-reactive protein and IL-6 (Almeida et al, 2017).  
 
      The proposed mechanism that links periodontitis with coronary heart disease 
is that the immune response in periodontitis affects systemic inflammatory burden 
by increasing the release of serum markers of inflammation. Several studies have 
shown that periodontitis is associated with increased levels of serum inflammatory 
markers involved in atherosclerosis. Loos at al. (2000) found higher serum 
concentrations of C-reactive protein, IL-6 and neutrophils in patients with 
generalized and localized periodontitis than in controls. A Case-control study 
showed an increased plasma concentration of risk markers for atherosclerosis 
such as C-reactive protein, fibrinogen and IL-18, particularly in patients with severe 
periodontitis (Buhlin, et al, 2009). Another study demonstrated that chronic 
periodontitis results in higher serum concentrations of C-reactive protein, IL-6, total 
leukocyte count and neutrophil. They found that patients in both chronic 
generalized and chronic localized periodontitis have higher mean CRP levels than 
in control group and that CRP level in the chronic generalized periodontitis group 
was statistically significant when compared to the control group (Gani et al, 2012).  
 
 
      Interventional studies showed that periodontal therapy can reduce systemic 
inflammation and level of serum inflammatory markers mainly C-reactive protein 
in otherwise healthy subjects (Caula et al, 2014; Leite et al, 2014). Recently, there 
is an increasing number of trials investigating the effect of mechanical non-surgical 
periodontal therapy in reducing levels of serum inflammatory markers in patients 
with coronary heart disease. The first prospective study to demonstrate the 
presence of higher circulating levels of the proinflammatory cytokines MCSF, IL-6, 
and IL-1b levels in patients with chronic stable angina compared with healthy 
controls, also showed that aspirin can reduce cytokines and CRP levels which may 
explain parts of its therapeutic action (Ikonomidis et al, 1999). A cross-sectional 
study found that serum hs-CRP levels in subjects with either angiographically 
proven coronary artery disease or chronic periodontitis were elevated two-fold 
compared with those of healthy individuals, whereas in subjects with both diseases 
(coronary artery disease plus chronic periodontitis) the levels were elevated three-
fold (Kumar et al, 2014). 
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     Bokhari et al. (2012) showed that in coronary heart disease patients with 
periodontitis, non-surgical mechanical periodontal therapy significantly reduced 
systemic levels of C-reactive protein, fibrinogen and white blood cells. Another 
study conducted by Zhou et al. (2013) concluded that non-surgical periodontal 
therapy decreased serum TNF-alpha, IL-6 and CRP levels in chronic periodontitis 
patients with stable coronary heart disease. Recently, Ertugrul et al. (2017) 
demonstrated that the level of systemic markers of atherosclerosis can be changed 
significantly in chronic periodontitis patients with concomitant atherosclerosis in 
comparison with systemically healthy patients and chronic periodontitis after non-
surgical periodontal treatment. This periodontal treatment modality, also known as 
scaling and root planning, is a routine dental procedure that involves removal of 
dental plaque and calculus from teeth surfaces including oral hygiene instructions 
to maintain oral health.  
 
 
      In this study, we aim to systematically review the literature to assess the quality 
of the included studies, and to determine if they provide any evidence on the effect 
of scaling and root planing, which is the routine periodontal treatment in 
maintaining lower level of serum inflammatory markers in patients with stable 
coronary heart disease. 
 
 
 
 
Objectives: 
 
   The aim of this study is to conduct a systematic review to investigate the effect 
of dental scaling and root planning on reducing the serum levels of inflammatory 
markers in patients with stable coronary heart disease.  
 
 
 
 
Materials and Method: 
 
 
Criteria for considering studies for this review 
 
Type of studies  
 
Studies assessing the effect of non-surgical scaling and root planing on the level 
of serum inflammatory markers in patients with stable coronary heart disease will 
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be included in the review. Randomized trials that compare the effect of non-
surgical periodontal therapy on serum inflammatory markers in subjects with 
coronary heart disease compared to those who have coronary heart disease but 
received no treatment or simple oral hygiene measures only, will be eligible for the 
inclusion in the systematic review as they represent the most definite way of 
determining whether a cause-effect relation exists between treatment and 
outcome.  
 
 
Type of participants  
 
Studies were eligible for the inclusion in this review when they fulfilled the      
following criteria:  
 
1. Patients with stable coronary heart disease confirmed by coronary 
angiography, and or history of angina or myocardial infarction.  
2. Patients with chronic periodontitis with pocket depths of 4 mm or more are 
measured at more than one site and have no acute dental infection. 
3. Included participants should not have received periodontal treatment within 
the past 6 months. 
4. Blood samples collected at baseline just before the scaling root planning and 
at follow up time ranges from 2 to 6 months. 
 
 
 Type of Intervention  
 
     The intervention is non-surgical mechanical periodontal therapy, a procedure 
involving supragingival and subgingival scaling and root planning of teeth with 
oral hygiene instructions will be compared to no treatment or only simple oral 
hygiene instructions.  
 
Type of Outcome measures  
 
▪ Primary outcome: 
The main outcome was chosen to be a sensitive indicator in predicting 
cardiovascular risk: Reduction in serum concentration of C-reactive protein 
 
▪ Secondary outcomes: 
       Reduction in serum concentration of other proinflammatory  
       biomarkers:  including IL-6, TNF- and fibrinogen  
 
 
Exclusion Criteria:  
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▪ Studies considered the use of adjunctive local or systemic antimicrobial 
therapy 
▪ Studies included smokers, pregnant patients or patients with other severe 
systemic conditions that could affect level of serum markers.  
▪ Pilot studies  
▪ Non-English literature 
▪ Animal studies.  
 
 
Electronic Searches 
 
The following databases were searched with no publication year or publication 
status restrictions: 
 
• PubMed (to May, 2018), using the strategy in Appendix 1 
• Scopus (to May, 2018), using the strategy in Appendix 2  
• Cochrane Central Register of Controlled Trials (CENTRAL) (to May, 2018), 
using the search strategy in Appendix 3  
 
Searching other resources 
 
The following trial registers were searched for completed studies: 
 
• U.S. National Institutes of Health Trials Registry (ClinicalTrials.gov) 
• World Health Organization (WHO) International Trials Registry Platform 
(www.who.int/ictrp/en/) 
 
Gray literature was searched using the following resource: 
• Google Scholar beta  
 
 
Search Strategy 
 
To identify studies considered for this review, searches conducted for each 
electronic database were modelled on a detailed search strategy developed for 
PubMed and modified for each database to accommodate differences in 
controlled vocabulary and syntax rules. The search was based on keywords 
and “Mesh” terms shown in appendices 1, 2 and 3.  
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   Selection Process 
 
The titles and abstracts identified through the electronic searches were 
screened and then assessed for eligibility criteria by full text as per PRISMA. 
RefWorks reference management software was used to merge search terms 
and deduplicate from the different databases. Studies not meeting the inclusion 
criteria were excluded and the reason for their exclusion is outlined (Table 2).  
The screening and selection process is demonstrated in a PRISMA flow 
diagram (Figure 1).  
 
 
 Data collection & management 
 
Data extraction template from Cochrane Consumers and Communication Review 
Group for included studies (2015) available at http://cccrg.cochrane.org/author-
resources, was used to record characteristics of the included studies in a table 
considering the following data (Table 1): 
 
• General information (author, year, title, journal, dental procedure) 
• Trial characteristics (sample size, type of study design, method of 
randomization, allocation concealment, blinding) 
• Type of intervention (number of intervention groups, time between 
intervention and blood sampling, frequency) 
• Characteristics of participants (total number of participants, age, gender, 
diagnostic criteria for both CVD and periodontitis) 
• Type of outcome measures (Outcomes definitions and unit of 
measurements, time of collection) 
• Miscellaneous (conclusion and source of funding/conflict of interest) 
 
 
Assessment for the Risk of Bias 
Two review authors independently assessed the risk of bias of the included 
randomized controlled trials using the Cochrane Collaboration tool criteria 
outlined in Chapter 8 of the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins et al, 2011), at http://handbook.cochrane.org.  
The following domains were assessed: 
 
• Sequence generation (selection bias) 
• Allocation concealment (selection bias) 
• Blinding of participants and personnel (performance bias) 
• Blinding of outcome assessment (detection bias) 
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• Incomplete outcome data (attrition bias) 
• Selective reporting (reporting bias) 
• Other potential sources of bias, such as confounding bias. 
The judgements for assessing the risk of bias were categorized as ‘low 
risk’, as ‘high risk, or as ‘unclear risk’ and interpreted as follows: 
 
• Low risk of bias: plausible bias unlikely to seriously alter the results if 
all domains were at low risk of bias. 
• Unclear risk of bias: plausible bias that raises some doubt about the 
results if one or more domains were at unclear risk of bias.  
• High risk of bias: plausible bias that seriously weakens confidence in 
the results if one or more domains were at high risk of bias. 
 
 
 
Statistical Analysis 
 
Assessment of heterogeneity 
 
Statistical heterogeneity, which is the percentage of variation across the studies 
not due to chance was assessed using the I2 statistics.  
 
• 25-50% small degree of heterogeneity  
• 50-75% moderate degree of heterogeneity 
• 75-100% large degree of heterogeneity 
 
Figure 1: Study Flow Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
PubMed (n= 106) 
Scopus (n= 134) 
Cochrane Library (n= 113) 
 
 
Additional records identified through 
Other sources 
ClinicalTrials.gov (n=1) 
Google scholar (n=4) 
 
Records after duplicates removed 
(n = 276) 
Records screened 
(n = 276)  
Records excluded 
(n = 240) 
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Results 
 
 
    A total of 358 studies were identified. Searching in PubMed and Scopus resulted 
in 106 and 134 studies, respectively. Searching in Cochrane Central Register of 
Controlled Trials resulted in 113 trials. Considering other sources, only 1 eligible 
study from clinicalTrials.gov and 4 eligible studies from Google Scholar could be 
retrieved. The search of the World Health Organization (WHO) International Trials 
Registry Platform resulted did not identify any relevant trial. After deduplications of 
the results using RefWorks reference management software, we resulted in 276 
studies. Screening by title and abstract resulted in the elimination of most of the 
studies that were clearly ineligible. Full text evaluation of the remaining 36 articles 
resulted in excluding 32 articles and the identification of 4 eligible studies 
assessing the effect of non-surgical periodontal therapy on serum inflammatory 
markers in patients with periodontitis and coronary heart disease (Table 1). 
Reasons for excluding the 32 articles after full text evaluation are listed in (Table 
Full-text articles assessed 
for eligibility 
(n = 36) Full text 
Full-text articles excluded, with 
reasons 
(n = 32) 
Pilot: (n= 3) 
Case-control: (n=1) 
Controlled clinical trial: (n=2) 
Mata-analysis: (n=1)  
Review: (n=3) 
Missing data: (n=1) 
Subjects in the control group not 
diagnosed with coronary heart 
disease: (n=14) 
CRP is not an outcome measure: (n=2) 
Non-English literature: (n=1) 
Irrelevant article: (n=1) 
Combing other interventions: (n=3) 
 
Studies included in 
qualitative synthesis 
(n = 4) 
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2). Refer to ‘Study flow chart’ showing the stages of the screening and the number 
of studies filtered at each stage (Figure 1).  
 
 
 
Study Characteristics 
 
    The four selected studies were randomized controlled trials published in English. 
One Study was conducted in Pakistan (Bokhari et al, 2012), One in China (Zhou 
et al, 2013), and two in India (Hada et al, 2015; Koppolu et al, 2013). The included 
studies involved a total of 502 participants with 307 patients in the intervention 
group and 195 in the control group. The mean age ranges from (49.00.6 to 
62.119.30) years in the intervention group and from (50.10.9 to 62.4812.24) 
years in the control group. In the study conducted by (Bokhari et al, 2012) 64 
subjects were dropped out from the trial due to changes in their medical history or 
due to personal and logistic reasons. Ten patients out the 64 were exited from the 
study because they received percutaneous cardiac intervention (PCI) or other 
cardiac intervention. In another study (Hada et al, 2015) twelve patients were 
excluded because they were hospitalized for cardiac reasons. Only one patient 
was lost from (Koppolu et al, 2013) study and no patient withdrew from the study 
by (Zhou et al, 2013). The intervention of the 4 studies was non-surgical scaling 
and root planing combining curettes and ultrasonic instruments at baseline with no 
adjunctive antimicrobial or laser therapy.  
     Although the included studies have met all planned inclusion criteria, they 
differed in many ways. Number of scaling and root planing sessions varied among 
the studies between 2 to 4 sessions in 24 hours to 3 weeks interval. In addition, 
the time for sample collections also differs among the trials. Other than baseline 
sample collection, one trial (Koppolu et al, 2013) considered re-sampling at 2 
months follow up and another trial (Zhou et al, 2013) at 3 months. In the study 
done by (Bokhari et al, 2012) blood samples were collected at two intervals, 1 
month and 2 months and in (Hada et al, 2015) blood sampling was at three 
intervals, 1 month, 3 months and 6 months follow ups. C- reactive protein was 
reported in all of the studies, whereas TNF- in 2 studies and IL-6 and Fibrinogen 
each in one study. Regarding the diagnostic criteria for stable coronary heart 
disease, two studies (Bokhari et al, 2012; Zhou et al, 2013) clearly stated that the 
diagnosis of stable CHD has to be proven angiographically. In the other two studies 
the criteria were history of cardiovascular event. Moreover, the studies considered 
different diagnostic criteria for periodontitis for the inclusion of their participants. 
Further details in ‘Characteristics of the included studies’ (Table 1).  
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Risk of Bias in Included Studies 
 
    Quality assessment of selected studies was performed with the Cochrane 
Collaboration tool for assessing risk of bias (Higgins et al, 2011).  
 
     Randomization was clearly reported in 2 studies, in which allocation of patients 
into intervention and control groups was concealed using sealed envelopes 
(Bokhari et al, 2012; Hada et al, 2015). In (Zhou et al, 2013) Patients were given 
the option to be in the intervention group or the treatment group, which considered 
a high risk of selection bias. The process of randomization and allocation 
concealment were not clearly described by (Koppolu et al, 2013).  
 
      Due to the nature of the intervention (scaling and root planing) blinding of 
patients was not possible in all of the trials. Blinding of outcome assessment was 
mentioned by two trials (Bokhari et al, 2012; Hada et al, 2015), but was not clear 
for the other two studies (Koppolu et al, 2013; Zhou et al, 2013). All of the studies 
demonstrated low risk attrition bias and selective reporting bias (Table 3). 
 
 
 
 
 
Effect of Intervention 
 
 
Primary outcome 
 
   All included randomized clinical trials have considered C-reactive protein (CRP) 
as their primary outcome. At baseline, there was no significant difference found in 
the level of (CRP) between the intervention and control groups in three of the 
studies (Bokhari et al, 2012; Koppolu et al, 2013; Zhou et al, 2013). One study 
noted a statistically significant difference in the level of (CRP) between the 
treatment and control groups (intergroup) at baseline (Hada et al, 2015), which 
remarkably contributed to heterogeneity among the studies. In addition, C-reactive 
protein along with other studies parameters were assessed at baseline before the 
intervention and over variable follow up periods of 2 months (Bokhari et al, 2012; 
Koppolu et al, 2013), 3 months (Hada et al, 2015; Zhou et al, 2013), and 6 months 
(Hada et al, 2015). Heterogeneity was calculated at baseline using the I2 statistics 
with 95% confidence interval, I2= 53%, which considered a moderate 
heterogeneity. Due to lack of consistency, it was difficult to pool the overall effect 
of in one forest plot.  
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      Three of the four RCTs showed a statistically significant reduction in the level 
of (CRP) in the intervention group compared to the control from baseline to follow 
up visits which ranged between 2 and 3 months (Bokhari et al, 2012; Koppolu et 
al, 2013; Zhou et al, 2013). Hada et al. (2015) observed statistically non-significant 
increase in the level of (CRP) in the intervention group compared with statistically 
significant increase in the control group at 6 months follow up (Table 4). Mean plot 
used to demonstrate IL- (Figure 2).  
  
 
 
 
 
 
 
 
 
 
 
 
    Figure 2: Mean plot: showing changes in mean differences over 
                     follow-up periods for C-reactive protein (CRP) 
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Secondary outcomes 
 
Secondary outcomes of our review include interleukin-6, Tumor necrosis factor- 
and Fibrinogen. There were variations between the included trials in considering 
the cardiovascular inflammatory risk markers being evaluated in each individual 
study. In regards to serum fibrinogen, only one study (Bokhari et al, 2012) have 
compared the change in its value between the intervention and the control group 
from baseline to 1 month and 2 months intervals. The study showed a significant 
reduction in the mean SE between baseline fibrinogen (367.110.4 mg/L) and at 
1 month follow up visit (305.38.7 mg/L) and 2 months visit (299.38.0 mg/L) only 
for the intervention group with a statistically significant difference (P =0.01) in 
comparison with the control group at 2 months follow up (335.911.8 mg/L). 
Comparing the change in tumor necrosis factor- (TNF-) level between 
intervention and control group was evaluated by two studies (Koppolu et al, 2013; 
Zhou et al, 2013). Koppolu et al. (2013) found a statistically significant (P <0.001) 
reduction in the mean value of serum (TNF-) in the intervention group from 
(22.141.46 to 20.21.61 pg/dl) compared to not statistically significant reduction 
in the control group (P >0.05) from (22.851.29 to 22.68 pg/dl) at 2 months follow 
up. Comparably, (Zhou et al, 2013) showed a reduction in the mean value of serum 
(TNF-) at 3 months follow up from baseline in the intervention group (39.8833.83 
pg/ml) to (28.9916.56 pg/ml) which was statistically significant (P =0.048), but not 
in the control group (49.6169.60 pg/ml) to (50.6486.33 pg/ml). Concerning 
serum interleukin-6 (IL-6), only one of the included trials had evaluated the 
reduction in its value from baseline to 3 months follow up visit (Zhou et al, 2013). 
The mean value of (IL-6) was statistically significantly reduced in the intervention 
group (P =0.049) from (38.6121.87 pg/ml) to (31.4020.32), but not in the control 
group, in which the value had increased (39.1224.31 pg/ml) to (42.5623.81 
pg/ml).  
 
 
 
 
Discussion 
 
 
    The aim of this study is to conduct a systematic review to investigate the effect 
of dental scaling and root planning on reducing the serum levels of inflammatory 
markers in patients with stable coronary heart disease. We summarized the current 
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literature of randomized clinical trials assessing the effect of routine non-surgical 
scaling and root planing on serum C-reactive protein, as the main outcome 
measure, fibrinogen, TNF- and interleukin-6 in patients with history of coronary 
heart disease and are clinically stable at the time of investigation.  
 
   The main limitation of the present systematic review is that the changes in serum 
levels of the inflammatory markers were assessed at different follow up (sampling) 
periods that ranges between 2 months (Bokhari et al, 2012; Koppolu et al, 2013), 
3 months (Hada et al, 2015; Zhou et al, 2013), and 6 months (Hada et al, 2015). 
This inconsistency makes it difficult to pool the results and to perform a meta-
analysis. Additional limitations of this review include the small number of included 
studies and the small sample sizes except for (Bokhari et al, 2012). Moreover, 
there were variations in the consideration of the secondary outcome measures 
among the trials.  
 
     In general, the results of the included randomized clinical trials appear to 
support the effectiveness of scaling and root planing in reducing serum levels of 
inflammatory markers C-reactive protein, fibrinogen, TNF- and interleukin-6 over 
a period of 2-3 months. However, random sequence generation was not clearly 
reported in one study (Koppolu et al, 2013) and in another study, the patients were 
given the option to be in the intervention group or the treatment group (Zhou et al, 
2013). In Hada et al. (2015) study, there was a slight increase in level of CRP over 
the follow up period in both the intervention and the control groups, but the increase 
in the intervention group was less significant compared to the control group at 6 
months. With the limited data on investigating the secondary outcomes, the studies 
indicate that scaling and root planing could have a positive effect on serum 
inflammatory markers fibrinogen, TNF- and interleukin-6. All the included studies 
demonstrated improvement in periodontal parameters along with the reduction in 
systemic inflammatory markers.  
 
    Chronic periodontitis is caused by bacteria attached to teeth surfaces and is 
characterized by gingival erythema, bleeding, loss of tooth surrounding 
structures, mobility and eventually tooth loss. It contributes to systemic 
inflammation characterized by elevation of acute phase proteins, including 
inflammatory cytokines such as interleukin-6, coagulation factors such as 
fibrinogen, and CRP (Lockhart et al, 2012). Induction of CRP in hepatocytes in 
response to inflammation is mainly regulated by cytokines like interleukin-6, 
interleukin-1 (Black et al, 2004), and Tumor necrosis factor- (Ebersole et al, 
2000). C-reactive protein has been strongly associated with coronary heart 
disease. A meta-analysis found relative risk for incident coronary heart disease 
was 1.58 (95% CI, 1.37 to 1.83) for CRP levels > 3.0 mg/L compared with CRP 
levels <1.0 mg/L (Buckley et al, 2009). A Framingham Heart Study to assess the 
role of CRP on vascular risk, concluded that CRP levels help to estimate risk for 
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initial cardiovascular events and may be used most effectively in persons at 
intermediate risk for vascular events (Wilson et al, 2008). The American College 
of Cardiology/American Heart Association 2013 guidelines on the assessment of 
cardiovascular risk, recommend the use of additional risk markers including hs-
CRP, when risk-based decisions about initiation of pharmacological therapy are 
uncertain, after quantitative risk assessment, with CRP with 2 mg/L support 
revising risk assessment (Goff et al, 2013).  
   
   Many pharmacological agents have been evaluated to suppress C-reactive 
protein. However, they have not been associated with atherosclerotic 
cardiovascular disease event reduction, or their predominant cardiovascular 
benefits could be attributed to another mechanism of action such as aspirin and 
statins (Martinez et al, 2018). Methotrexate suppresses systemic inflammation 
including serum CRP was associated with a 21% lower risk for total CVD (n = 10 
studies, 95% confidence interval [CI] 0.73 to 0.87, p <0.001) and an 18% lower 
risk for myocardial infarction (n = 5, 95% CI 0.71 to 0.96, p = 0.01) in systematic 
review and meta-analysis on patients with rheumatoid arthritis, psoriasis, or 
polyarthritis (Micha et al, 2011). 
 
 
   With the limitations of the available evidence, it suggests that routine non-
surgical periodontal therapy, which mainly consists of scaling and root planing of 
the dentition, may progressively reduce level of CRP and other serum 
inflammatory markers between periodontal maintenance visits in patients with 
stable coronary heart disease. Scaling and root planing considered a safe anti-
inflammatory intervention (Achtari et al, 2012), in which the majority of cases do 
not require antimicrobial pharmacological agents and thus reducing the potential 
for adverse events and offering new treatment options for patients with 
contraindications for anti-inflammatory medications such as statins or aspirin 
(Demmer et al, 2013).   
 
   More prospective randomized clinical trials of longer follow up durations are 
required to sufficiently assess whether routine periodontal treatment with the 
maintenance of good oral hygiene would add a value in the prevention secondary 
vascular events by reducing systemic inflammatory burden in patient with stable 
coronary heart disease. However, it might be unethical to rely on RCTs to assess 
the effect of scaling and root planing over a long follow up duration, > 6 months, 
in which the participants in the control group need to be precluded from receiving 
prophylactic scaling and root planing for the maintenance of their oral health. 
Instead, well-designed observational studies, such as cohort or case-control designs 
may add a value in evaluating the effect of scaling and root planing on cardiovascular 
risk. Interpretation of the results obtained from both RCTs and observational 
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studies can help understand the efficacy/effectiveness and safety of a 
therapeutic option (Faraoni & Schaefer, 2016). Most of the observational studies 
were conducted to correlate coronary heart disease with periodontal disease, but 
not periodontal interventions. A retrospective cohort study used insurance 
claimed data from 338,891 individuals followed up from 2005 to 2009, 
investigated the effect of periodontal treatment on medical costs and 
hospitalization among individuals with type 2 diabetes, coronary heart disease, 
cerebral vascular disease, rheumatoid arthritis, and pregnancy. They found that 
patients with diabetes or cardiovascular disease showed a significant 20%-40% 
reductions in both outcomes relative to controls, which appeared to persist up to 
3 years after initial periodontal therapy (Jeffcoat et al,2014).  
 
   Furthermore, testing biomarkers such as total cholesterol, low-density 
lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol, triglycerides, 
serum creatinine (estimated glomerular filtration), and fasting blood glucose for 
the evaluation of modifiable risk factors for the progression of atherosclerosis is 
also fundamental to direct secondary preventive measures in patients with stable 
coronary heart disease (Morrow et al, 2010).   
 
 
  
 
Conclusion 
 
    There is a low evidence from the current literature supporting the effect of 
scaling and root planing in reducing systemic inflammatory markers including C-
reactive protein, tumor necrosis factor- (TNF-), interleukin-6 (IL-6), and 
fibrinogen in patients with coronary heart disease. Future research should 
include observational studies to assess the effect of scaling and root planing in 
reducing the inflammatory burden in this targeted population and the risk of 
secondary cardiovascular event. 
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Table 1: Characteristics of Included studies  
Author(s)
, year 
Study 
desig
n 
Sample 
size 
Periodontal  
therapy 
Diagnostic 
Criteria for 
Coronary heart 
disease 
Diagnostic 
Criteria for 
Periodontal 
disease 
Intervals 
between 
blood 
samples 
Outcome 
measures 
Conclusion 
Bokhari 
et al, 
2013 
RCT n = 317 
 
Interventio
n group (n 
=212) 
 
Control 
group (n 
=105) 
 
Non-
surgical 
periodontal 
therapy 
included 
supra- and 
sub-gingival 
scaling and 
root 
planning 
and oral 
hygiene 
instructions  
in 2 to 4 
visits within 
10 days 
 
Stable 
angiographicall
y proven CHD; 
defined having 
> 50% stenosis 
of >1 coronary 
artery 
documented 
by 
angiography 
 4 teeth 
with 1 site 
with 
periodontal 
probing 
depth 
(PPD)  4 
mm and 
clinical 
attachment 
level (CAL) 
 3 mm at 
same site, 
bleeding 
on Probing 
(BOP) 
>20% 
 
Blood 
samples 
collected 
between 
8 a.m.-12 
p.m. (to 
control 
diurnal 
variations
) at 
baseline, 
at 1 
month 
and 2 
months 
follow up 
visits. 
Primary 
outcome: 
Change in 
CRP level 
at 1 and 2 
months 
after 
completion 
of SRP 
 
 
Secondar
y 
outcome: 
Fibrinogen 
and WBCs 
level at 2 
months 
after 
completion 
of SRP 
 
CRP baseline (mg/L): 
Control: 4.20.3  
Intervention: 4.40.2  
 
CRP at 1 month 
(mg/L): 
Control: 4.10.3  
Intervention: 3.40.2  
 
CRP at 2 months 
(mg/L): 
Control: 4.10.3  
Intervention: 3.10.2  
 
Fibrinogen baseline 
(mg/L): 
Control: 339.610.5  
Intervention:367.110.
4  
 
Fibrinogen at 1 
month (mg/L):  
Control: 325.59.6  
Intervention:305.3.38
.7  
 
Fibrinogen at 2 
months (mg/L):  
Control: 335.911.8  
Intervention:299.3 
8.0  
 
Hada et 
al, 2015 
RCT n = 70 
 
Interventio
n group (n 
=35) 
 
Non-
surgical 
periodontal 
therapy 
included 
scaling and 
root planing 
and oral 
Stable CHD, 
including 
stable angina, 
STEMI and 
non-STEMI 
and in which 
symptoms 
remained 
Mild to 
moderate 
chronic 
periodontiti
s with  4 
teeth with 
clinical 
attachment 
Blood 
samples 
collected 
at 
baseline, 
and at 1, 
3, and 6 
months 
Primary 
outcome: 
Change in 
CRP level 
at 1, 3, and 
6 months 
after 
completion 
of SRP 
CRP baseline (mg/L): 
Control: 3.622.31  
Intervention: 
5.102.00  
 
CRP at 1 month 
(mg/L): 
Control: 4.312.43  
Intervention: 
6.211.92  
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Control 
group (n 
=35) 
 
hygiene 
instructions 
in 2 sittings 
with 24 
hours 
interval 
stable for at 
least 60 days 
and no 
evidence of 
recent 
myocardial 
damage 
loss (CAL) 
 4 mm at 
 1 site 
 
follow up 
visits 
 
 
Secondar
y 
outcome: 
Changes in 
lipid profile, 
WBC 
profile, and 
systolic BP 
at 1, 3, and 
6 months 
after 
completion 
of SRP   
 
CRP at 3 months 
(mg/L): 
Control: 4.091.82  
Intervention: 
6.223.64  
 
CRP at 6 months 
(mg/L): 
Control: 4.942.04  
Intervention: 
6.307.53  
 
Koppolu 
et al, 
2013 
RCT n = 40 
 
Interventio
n group (n 
=20) 
 
Control 
group (n 
=20) 
 
Non-
surgical 
periodontal 
therapy 
included 
scaling and 
root planing 
performed 
once a 
week for 3 
weeks 
History of 
myocardial 
infarction 
Probing 
depth of  
5 mm 
evaluated 
at 4 sites 
per tooth 
Blood 
samples 
collected 
at 
baseline 
and at 8 
weeks 
follow up 
visit 
Primary 
outcome: 
Change in 
CRP and 
TNF-alpha 
level at 8 
weeks 
CRP baseline (g/dl): 
Control: 0.470.11  
Intervention: 
0.450.12 
 
CRP at week 8 
(g/dl): 
Control: 0.450.14  
Intervention: 
0.290.12 
 
TNF- at baseline 
(pg/dl): 
Control: 22.851.29  
Intervention: 
22.141.46  
 
TNF- at week 8 
(pg/dl): 
Control: 22.681.23  
Intervention: 
20.201.61  
 
Zhou et 
al, 2013 
RCT n = 75 
 
Interventio
n group (n 
=40) 
 
Control 
group (n 
=35) 
 
Non-
surgical 
periodontal 
therapy 
included 
supragingiv
al scaling 
and four 
sessions of 
quadrant 
root 
debridement 
with oral 
hygiene 
instructions  
Stable CHD 
with one of the 
following 
criteria: 
previous 
history of 
myocardial 
infarction, or 
angioplasty 
surgery more 
than 6 months 
previously, or 
proven 
coronary or left 
main stem 
vessel 
obstruction by 
more than 50% 
by 
angiography 
 
More than 
30% of 
teeth with 
probing 
depth (PD)  
 4 mm 
and clinical 
attachment 
loss (CAL) 
 3 mm, 
and with 
alveolar 
bone loss 
>30% of 
the root 
length 
shown on 
Panoramic 
radiograph. 
In addition, 
at least 2 
teeth 
showed 
both (PD) 
 5 mm 
and (CAL) 
 3 mm 
distributed 
in different 
quadrants 
Blood 
samples 
collected 
between 
8 a.m.- 
10 a.m. 
at 
baseline 
and at 3 
months 
follow up 
visit 
Primary 
outcome: 
Change in 
CRP, TNF- 
alpha and 
IL-6 serum 
level at 3 
months  
 
Secondar
y 
outcomes
: 
Change in 
WBC 
counts, 
total 
cholesterol, 
triglyceride, 
HDL, LDL 
and blood 
glucose 
level at 3 
months  
 
CRP baseline (mg/L): 
Control: 2.963.55 
Intervention: 
2.613.16  
 
CRP 3 months 
(mg/L): 
Control: 2.943.62  
Intervention: 
2.062.54  
 
TNF- at baseline 
(pg/dl): 
Control: 49.6169.60  
Intervention: 
39.8833.83  
 
TNF- at 3 months 
(pg/dl): 
Control: 50.6486.33  
Intervention: 
28.9916.56  
 
IL-6 at baseline 
(pg/dl): 
Control: 39.1224.31  
Intervention: 
38.6121.87 
 
IL-6 at 3 months 
(pg/dl): 
Control: 42.5623.81 
Intervention: 
31.4020.32 
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Table 2: Characteristic of Excluded Studies 
Study Reason for exclusion 
Arrol et al. (2015). Relationship of root canal 
treatment to C-reactive protein as an 
inflammatory marker for cardiovascular 
disease 
 
Root canal therapy is the only dental 
intervention 
Arvanitidis et al. (2017) Reduced platelet 
hyper-reactivity and platelet-leukocyte 
aggregation after periodontal therapy 
 
Controlled clinical trial and different 
outcome measures for the evaluation of 
cardiovascular risk 
Beck et al. (2008). The Periodontitis and 
Vascular Events (PAVE) pilot study: 
adverse events 
 
Pilot Study  
Bresolin et al. (2013). Lipid profiles and 
inflammatory markers after periodontal 
treatment in children with congenital heart 
disease and at risk for atherosclerosis 
 
Pediatric Population with variations in 
the diagnosis of congenital heart 
diseases 
Caula et al. (2014). The effect of periodontal 
therapy on cardiovascular risk markers: A 6-
month randomized clinical trial 
 
Subjects with periodontits were not 
diagnosed with coronary heart disease 
D’Aiuto et al. (2006). Periodontal infections 
cause changes in traditional and novel 
cardiovascular risk factors: results from a 
randomized controlled clinical trial. 
 
Subjects with periodontitis were 
systemically healthy 
D’Aiuto et al. (2005). Short-term effects of 
intensive periodontal therapy on serum 
inflammatory markers and cholesterol 
 
Subjects with periodontitis were 
systemically healthy 
D’Aiuto et al. (2004). Periodontitis and 
atherogenesis: Causal association or simple 
coincidence 
 
Pilot Study 
Subjects with periodontitis were 
systemically healthy 
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D’Aiuto et al. (2007). Acute effects of 
periodontal therapy on bio-markers of 
vascular health 
 
Subjects with periodontitis were 
systemically healthy 
Follow and up to 30 days 
Gao et al. (2016). Effects of essential 
periodontal treatment on serum level of 
sCD40L and periodontal clinical parameters 
in patients with moderate to severe 
periodontitis at high risk of stroke 
 
Different outcome measures 
Non- English literature (Chinese) 
Ide et al. (2003). Effect of treatment of 
chronic periodontitis on levels of serum 
markers of acute-phase inflammatory and 
vascular responses 
 
Subjects with periodontitis not coronary 
heart disease 
 
Javed et al. (2016). Effect of Nd:YAG laser-
assisted non-surgical periodontal therapy on 
clinical periodontal and serum biomarkers in 
patients with and without coronary artery 
disease: A short-term pilot study 
 
Pilot study  
Intervention is laser assisted non-
surgical periodontal therapy 
Lapez et al. (2012). Effects of periodontal 
therapy on systemic markers of 
inflammation in patients with metabolic 
syndrome: A controlled clinical trial 
 
Subjects with metabolic syndrome 
Controlled clinical trial 
 
 
 
Leite et al. (2014). Effects of periodontal 
therapy on C-reactive protein and HDL in 
serum of subjects with periodontitis 
 
Subjects with periodontitis were 
systemically healthy 
Li et al. (2011). Effect of periodontal 
treatment on circulating CD34 + cells and 
peripheral vascular endothelial function: A 
randomized controlled trial 
 
Subjects with periodontitis were 
systemically healthy 
Different outcome measures 
Lobo et al. (2016). Treating Periodontal 
Disease in Patients With ST-Elevation 
Myocardial Infarction: A Randomized 
Clinical Trial  
 
Missing Data  
Lowe (2004) Dental Disease, Coronary 
Heart Disease and Stroke, and 
Inflammatory Markers: What Are the 
Associations, and What Do They Mean? 
 
Review article  
 22 
Merchant et al. (2017). Evaluating 
Periodontal Treatment to Prevent 
Cardiovascular Disease: challenges and 
Possible Solutions 
 
Review article 
Meuman et al. (2004). Oral health, 
atherosclerosis, and cardiovascular disease 
 
Review article  
Monteiro et al. (2012). Measurement of the 
nonlinear optical response of low-density 
lipoprotein solutions from patients with 
periodontitis before and after periodontal 
treatment: evaluation of cardiovascular risk 
markers 
 
Study excluded patients with history of 
cardiovascular disease 
Payne et al. (2011). The effect of 
subantimicrobial-dose-doxycycline 
periodontal therapy on serum biomarkers of 
systemic inflammation: a randomized, 
double-masked, placebo-controlled clinical 
trial 
 
Periodontal therapy included use of 
doxycycline 
Ramarez et al. (2014). Biomarkers of 
cardiovascular disease are increased in 
untreated chronic periodontitis: A case 
control study 
 
Case control study 
Renvert et al. (2009). Short-term effects of 
an anti-inflammatory treatment on clinical 
parameters and serum levels of C-reactive 
protein and proinflammatory cytokines in 
subjects with periodontitis 
 
Intervention included a combination of 
dipyridamole and prednisolone (CRx-
102)  
 
 
Sharma et al. (2014). A study of C-reactive 
protein, lipid metabolism and peripheral 
blood to identify a link between periodontitis 
and cardiovascular disease 
 
Subjects with periodontitis were 
systemically healthy 
 
Skilton et al. (2011). The effect of a 
periodontal intervention on cardiovascular 
risk markers in Indigenous Australians with 
periodontal disease: The PerioCardio study 
 
Study excluded patients with history of 
cardiovascular disease 
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Seymour et al. (1998). Is there a link 
between periodontal disease and coronary 
heart disease? 
 
Meta-analysis 
Tuter et al. (2007). Effects of scaling and 
root planing and sub-antimicrobial dose 
doxycycline on oral and systemic 
biomarkers of disease in patients with both 
chronic periodontitis and coronary artery 
disease 
 
Both intervention and control groups 
received periodontal therapy with/or 
without doxycycline respectively  
Taylor et al. (2010). The effect of initial 
treatment of periodontitis on systemic 
markers of inflammation and cardiovascular 
risk: A randomized controlled trial 
 
Participants not diagnosed with coronary 
heart disease 
 
Thaker et al. (2010). Evaluation of the C-
reactive protein serum levels in periodontitis 
patients with or without atherosclerosis 
 
Case control study  
Tonetti et al. (2007). Treatment of 
periodontitis and endothelial function 
 
 
Study excluded patients with history of 
cardiovascular disease 
Tonregeani et al. (2016). Evaluation of 
periodontitis treatment effects on carotid 
intima-media thickness and expression of 
laboratory markers related to 
atherosclerosis 
 
Different outcome measures 
Vidal et al. (2009). Periodontal therapy 
reduces plasma levels of interleukin-6, C-
reactive protein, and fibrinogen in patients 
with severe periodontitis and refractory 
arterial hypertension 
 
Participants not diagnosed with coronary 
heart disease 
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Table 3: Risk of Bias Assessment  
Study  Random 
sequence 
generation 
Allocation 
concealment  
Blinding of 
participants 
and 
personnel  
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
reporting  
Bokhari et 
al , 2013 
      
Hada et al, 
2015 
      
Koppolu et 
al, 2013 
 
 
    
Zhou et al, 
2013 
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           Key:         Low risk                 High risk              unclear  
 
Standard Deviation: *, Standard Error: ^ 
 
Appendices: 
 
Appendix 1:  
 PubMed=106: ((("Cardiovascular Diseases"[Mesh] OR Cardiovascular Diseases OR 
Cardiovascular Disease OR Cardiovascular OR arteriosclerosis OR atherosclerosis OR 
"Atherosclerosis"[Mesh] OR "Arteriosclerosis"[Mesh] OR "Myocardial Ischemia"[Mesh] 
OR "Acute Coronary Syndrome"[Mesh] OR Myocardial Ischemia OR ischemic heart 
disease OR ischemic heart diseases OR myocardial infarction OR myocardial infarctions 
OR "Myocardial Infarction"[Mesh] OR Myocardial Infarct OR coronary diseases OR 
coronary disease OR coronary heart diseases OR coronary heart disease OR "Coronary 
Disease"[Mesh])) AND (((alveolar bone OR "Alveolar Bone Loss"[Mesh] OR "Bone 
Resorption"[Mesh] OR Alveolar bone loss OR "bone loss" OR periodontal attachment 
loss OR "Periodontal Attachment Loss"[Mesh] OR periodontitis OR periodontal disease 
 
Table 4: Changes in CRP level over follow up periods 
Study  Sample Size  CRP at Baseline  CRP at 1 month  CRP at 2 months  CRP at 3 months  CRP at 6 months  
Bokhari et al, 
2013 
Control 
group 
(n= 85) 
Intervention 
(n= 161) 
 
Total n= 246 
Control: 
(4.2 0.3 mg/L)^ 
(4.2 2.8 mg/L)* 
Intervention: 
(4.40.2 mg/L)^ 
(4.4 2.5 mg/L)* 
Control: 
(4.10.3 mg/L)^ 
(4.1 2.8 mg/L)* 
Intervention: 
(3.40.2 mg/L)^ 
(3.4 2.5 mg/L)* 
 
 
Control:  
(4.10.3 mg/L)^  
(4.1 2.8 mg/L)* 
Intervention: 
(3.10.2 mg/L)^ 
(3.1 2.5 mg/L)* 
 
 
      
Not Applicable 
 
      
 
     Not Applicable 
Hada et al, 
2015 
Control 
group 
(n= 25) 
Intervention 
(n= 30) 
 
Total n= 55 
Control: 
(3.622.31 mg/L)* 
Intervention: 
(5.102.00 mg/L)*  
 
Control:  
(4.312.43 
mg/L)*  
Intervention: 
(6.211.92 
mg/L)*  
 
 
 
Not Applicable 
 
Control:  
(4.091.82 mg/L)*  
Intervention: 
(6.223.64 mg/L)*  
 
Control: 
(4.942.04 mg/L)*  
Intervention: 
(6.307.53 mg/L)*  
 
Koppolu et al, 
2013 
Control 
group 
(n= 19) 
Intervention 
(n= 20) 
 
 
Total n= 39 
Control:  
(0.470.11 g/dl)*  
Intervention: 
(0.450.12 g/dl)*  
 
 
 
Not Applicable 
 
Control:  
(0.450.14 g/dl)* 
Intervention: 
(0.290.12 g/dl)* 
 
 
 
Not Applicable 
 
 
 
Not Applicable 
 
Zhou et al, 
2013 
Control 
group 
(n= 35) 
Intervention 
(n= 40) 
 
Total n= 75 
Control:  
(2.963.55 mg/L)* 
Intervention: 
(2.613.16 mg/L)*  
 
Not Applicable 
 
Not Applicable 
 
Control:  
(2.943.62 mg/L)*  
Intervention: 
(2.062.54 mg/L)*  
 
Not Applicable 
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OR periodontal diseases OR "Periodontal Diseases"[Mesh] OR "Gingival 
Diseases"[Mesh] OR chronic periodontitis OR Gingival disease OR Gingival diseases OR 
"Chronic Periodontitis"[Mesh] OR periodontal index OR "Periodontal Index"[Mesh] OR 
"Gingival Pocket"[Mesh] OR "Periodontal Pocket"[Mesh])) OR (periodontal therapy OR 
periodontal treatment OR periodontal treatments OR periodontal index OR "Periodontal 
Index"[Mesh] OR dental prophylaxis OR "Dental Prophylaxis"[Mesh] OR periodontal 
debridement OR subgingival debridement OR subgingival curettage OR "Periodontal 
Debridement"[Mesh] OR "Subgingival Curettage"[Mesh] OR scaling OR "Dental 
Scaling"[Mesh] OR root planing OR "Root Planing"[Mesh] OR scaling root planing OR 
subgingival scaling OR supragingival scaling OR non-surgical dental OR non-surgical 
periodontal OR non-surgical dental therapy OR non-surgical periodontal therapy OR non-
surgical periodontal treatment))) AND (Biomarkers OR "Biomarkers"[Mesh] OR Bio-
marker OR inflammatory markers OR serum markers OR biological markers OR plasma 
level OR inflammatory mediators OR Proinflammatory mediators OR Pro-inflammatory 
mediators OR Pro-inflammatory mediator OR Proinflammatory mediator OR inflammatory 
mediator OR inflammatory marker OR biomarker OR serum marker OR interleukin OR 
interleukins OR "Interleukins"[Mesh] OR IL6 OR IL-6 OR interleukin 6 OR "Interleukin-
6"[Mesh] OR "IL6 protein, human" [Supplementary Concept] OR Tumor Necrosis Factor-
alpha OR Tumour Necrosis Factor-alpha OR tumor necrosis-alpha OR tumor necrosis 
factor-α OR “Tumor Necrosis Factor-alpha"[Mesh] OR "TNF protein, human" 
[Supplementary Concept] OR tnf alpha OR tnf-alpha OR tnf-α OR c-reactive protein OR 
"C-Reactive Protein"[Mesh] OR C-reactive proteins OR cytokines OR cytokine OR 
"Cytokines"[Mesh] OR fibrinogen OR "Fibrinogen"[Mesh] OR fibrinogens OR "Gingival 
Crevicular Fluid/chemistry"[Mesh] OR "Gingiva/immunology"[Mesh]) Filters: Randomized 
Controlled Trial; Clinical Trial  
 
 
 Appendix 2:  
Scopus=134: ( TITLE-ABS-KEY ( cardiovascular  W/2  disease* )  OR  TITLE-ABS-KEY 
( cardiovascular )  OR  TITLE-ABS-KEY ( arteriosclerosis )  OR  TITLE-ABS-KEY ( 
atherosclerosis )  OR  TITLE-ABS-KEY ( acute  PRE/0  coronary  PRE/0  syndrome* 
)  OR  TITLE-ABS-KEY ( {Myocardial Ischemia} )  OR  TITLE-ABS-KEY ( 
ischemic  PRE/0  heart  PRE/0  disease* )  OR  TITLE-ABS-KEY ( 
myocardial  PRE/0  infarct* )  OR  TITLE-ABS-KEY ( coronary  W/2  disease* ) )  AND  ( 
TITLE-ABS-KEY ( {alveolar bone} )  OR  TITLE-ABS-KEY ( {Alveolar Bone Loss} 
)  OR  TITLE-ABS-KEY ( bone  W/2  resorption )  OR  TITLE-ABS-KEY ( {Periodontal 
attachment loss} )  OR  TITLE-ABS-KEY ( periodontitis )  OR  TITLE-ABS-KEY ( 
periodont*  W/2  disease* )  OR  TITLE-ABS-KEY ( {chronic periodontitis} )  OR  TITLE-
ABS-KEY ( gingiva*  W/2  disease* )  OR  TITLE-ABS-KEY ( periodontal  PRE/0  ind* 
)  OR  TITLE-ABS-KEY ( gingival  PRE/0  pocket* )  OR  TITLE-ABS-KEY ( 
periodontal  PRE/0  pocket* ) )  OR  ( TITLE-ABS-KEY ( periodont*  W/2  therapy 
)  OR  TITLE-ABS-KEY ( periodont*  W/2  treatment* )  OR  TITLE-ABS-KEY ( 
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periodontal  PRE/0  ind* )  OR  TITLE-ABS-KEY ( {dental prophylaxis} )  OR  TITLE-ABS-
KEY ( periodont*  W/2  debridement* )  OR  TITLE-ABS-KEY ( 
subgingival  PRE/0  debridement* )  OR  TITLE-ABS-KEY ( 
subgingival  PRE/0  curettage )  OR  TITLE-ABS-KEY ( scaling )  OR  TITLE-ABS-KEY ( 
root  PRE/0  planing )  OR  TITLE-ABS-KEY ( scaling  PRE/0  root  PRE/0  planing 
)  OR  TITLE-ABS-KEY ( subgingival  PRE/0  scaling )  OR  TITLE-ABS-KEY ( 
supragingival  PRE/0  scaling )  OR  TITLE-ABS-KEY ( non-surgical  W/2  dental 
)  OR  TITLE-ABS-KEY ( non-surgical  W/2  periodont* )  OR  TITLE-ABS-KEY ( non-
surgical  AND dental  AND therapy )  OR  TITLE-ABS-KEY ( non-
surgical  PRE/0  periodontal  PRE/0  therapy )  OR  TITLE-ABS-KEY ( non-
surgical  PRE/0  periodontal  PRE/0  treatment ) )  AND  ( TITLE-ABS-KEY ( biomarkers 
)  OR  TITLE-ABS-KEY ( bio-marker )  OR  TITLE-ABS-KEY ( inflammat*  W/2  marker* 
)  OR  TITLE-ABS-KEY ( serum  W/2  marker* )  OR  TITLE-ABS-KEY ( 
biological  PRE/0  marker* )  OR  TITLE-ABS-KEY ( {plasma level} )  OR  TITLE-ABS-
KEY ( inflammat*  W/2  mediator* )  OR  TITLE-ABS-KEY ( proinflammatory  AND 
mediator* )  OR  TITLE-ABS-KEY ( pro-inflammatory  AND mediator* )  OR  TITLE-ABS-
KEY ( interleukin )  OR  TITLE-ABS-KEY ( interleukins )  OR  TITLE-ABS-KEY ( il6 
)  OR  TITLE-ABS-KEY ( il-6 )  OR  TITLE-ABS-KEY ( interleukin  6 )  OR  TITLE-ABS-
KEY ( tumor  AND necrosis  AND factor-alpha )  OR  TITLE-ABS-KEY ( tumour  AND 
necrosis  AND factor-alpha )  OR  TITLE-ABS-KEY ( tumor  AND necrosis  AND factor-α 
)  OR  TITLE-ABS-KEY ( tnf  PRE/0  alpha )  OR  TITLE-ABS-KEY ( tnf-α )  OR  TITLE-
ABS-KEY ( c-reactive  AND protein* )  OR  TITLE-ABS-KEY ( cytokine* )  OR  TITLE-
ABS-KEY ( fibrinogen* )  OR  TITLE-ABS-KEY ( gingiva*  W/2  immunology ) )  AND  ( 
LIMIT-TO ( EXACTKEYWORD ,  "Clinical Trial" )  OR  LIMIT-TO ( EXACTKEYWORD 
,  "Randomized Controlled Trial" ) )   
 
Appendix 3:   
Cochrane Library=269 (113 Trials): ([mh "Cardiovascular Diseases"] OR Cardiovascular 
Diseases OR Cardiovascular Disease OR Cardiovascular OR arteriosclerosis OR 
atherosclerosis OR [mh "Atherosclerosis"] OR [mh "Arteriosclerosis"] OR [mh "Myocardial 
Ischemia"] OR [mh "Acute Coronary Syndrome"] OR Myocardial Ischemia OR ischemic 
heart disease OR ischemic heart diseases OR myocardial infarction OR myocardial 
infarctions OR [mh "Myocardial Infarction"] OR Myocardial Infarct OR coronary diseases 
OR coronary disease OR coronary heart diseases OR coronary heart disease OR [mh 
"Coronary Disease"]) AND (alveolar bone OR [mh "Alveolar Bone Loss"] OR [mh "Bone 
Resorption"] OR Alveolar bone loss OR "bone loss" OR periodontal attachment loss OR 
[mh "Periodontal Attachment Loss"] OR periodontitis OR periodontal disease OR 
periodontal diseases OR [mh "Periodontal Diseases"] OR [mh "Gingival Diseases"] OR 
chronic periodontitis OR Gingival disease OR Gingival diseases OR [mh "Chronic 
Periodontitis"] OR periodontal index OR [mh "Periodontal Index"] OR [mh "Gingival 
Pocket"] OR [mh "Periodontal Pocket"] OR periodontal therapy OR periodontal treatment 
OR periodontal treatments OR periodontal index OR [mh "Periodontal Index"] OR dental 
prophylaxis OR [mh "Dental Prophylaxis"] OR periodontal debridement OR subgingival 
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debridement OR subgingival curettage OR [mh "Periodontal Debridement"] OR [mh 
"Subgingival Curettage"] OR scaling OR [mh "Dental Scaling"] OR root planing OR [mh 
"Root Planing"] OR scaling root planing OR subgingival scaling OR supragingival scaling 
OR non-surgical dental OR non-surgical periodontal OR non-surgical dental therapy OR 
non-surgical periodontal therapy OR non-surgical periodontal treatment) AND 
(Biomarkers OR [mh "Biomarkers"] OR Bio-marker OR inflammatory markers OR serum 
markers OR biological markers OR plasma level OR inflammatory mediators OR 
Proinflammatory mediators OR Pro-inflammatory mediators OR Pro-inflammatory 
mediator OR Proinflammatory mediator OR inflammatory mediator OR inflammatory 
marker OR biomarker OR serum marker OR interleukin OR interleukins OR [mh 
"Interleukins"] OR IL6 OR IL-6 OR interleukin 6 OR [mh "Interleukin-6"] OR [mh"IL6 
protein, human"] OR Tumor Necrosis Factor-alpha OR Tumour Necrosis Factor-alpha 
OR tumor necrosis-alpha OR tumor necrosis factor-α OR [mh "Tumor Necrosis Factor-
alpha"] OR [mh "TNF protein, human"] OR tnf alpha OR tnf-alpha OR tnf-α OR c-reactive 
protein OR [mh "C-Reactive Protein"] OR C-reactive proteins OR cytokines OR cytokine 
OR [mh "Cytokines"] OR fibrinogen OR [mh "Fibrinogen"] OR fibrinogens OR [mh 
"Gingival Crevicular Fluid"/CH] OR [mh "Gingiva"/IM])  
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